Long-term Safety and Performance of CMF Porous Titanium Implants
← catalyst calendarNCT06910033 · readout ≤ 102 d
Sponsored by Materialise (industry) · MTLS.BR — their whole pipeline →.
Phase
—
Status
Not yet recruiting
Study type
Observational
Enrollment
200estimated
Sites
2
Countries
Denmark, France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Nov 2025 | estimated | When the study began enrolling |
| Primary completion | Nov 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Craniofacial Defects
Intervention
- Device: Craniomaxillofacial (CMF) porous titanium implant
Primary outcome
what the primary-completion date above is the date OFLast visit success rate of the device after the surgical implantation of Materialise patient-specific CMF Porous Titanium Implants
measured Last visit (up to 8 years post-implantation)
Permalink · MTLS.BR's whole pipeline · Catalyst calendar · Every registered study · What changed